Balaxi Pharmaceuticals Limited

To

25th August, 2021

Listing Department,

National Stock Exchange of India Limited.

Exchange Plaza, Plot No C/1, G Block, Bandra Kurla Complex,

Bandra (E), Mumbai-400051

Stock Code: BALAXI

Sub: Proceedings of 78th Annual General meeting held on 25th August, 2021

Dear Sir/Madam,

With reference to the above stated subject, in compliance with Regulation 30 read with Schedule-III of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the proceedings of the 78th Annual General Meeting of Balaxi Pharmaceuticals Limited held on Wednesday, 25th August, 2021, at 11:00 AM through Video Conferencing ("VC") /Other Audio Visual Means ("OAVM") without the physical presence of the Members at a common venue in compliance with General Circulars issued by Ministry of Corporate Affairs (MCA Circulars) and circulars issued by Securities Exchange Board of India are enclosed for your reference.

The Voting results will be intimated to the exchange separately.

This is for your information and records.

Yours Faithfully,

For Balaxi Pharmaceuticals Limited

Chinta Shalini

Company Secretary

Registered Office:

Balaxi Pharmaceuticals Limited

Summary of the proceedings of the 78th Annual General Meeting

The 78th Annual General Meeting (AGM) of the members of Balaxi Pharmaceuticals Limited (the Company) was held on Wednesday, 25th August, 2021, at 11:00 AM through Video Conferencing ("VC")/Other Audio Visual Means ("OAVM") without the physical presence of the Members at a common venue in compliance with Circular No. 14/2020, Circular No. 17/2020, Circular no. 02/2021 issued by Ministry of Corporate Affairs (MCA Circulars), Circulars issued by Securities Exchange Board of India and other applicable provisions of the Companies Act, 2013 and concluded at 11:16 AM.

The meeting was attended by 26 members through VC or OAVM.

Mr. Ashish Maheshwari, Chairman of the Company occupied the Chair and on being satisfied that sufficient quorum was present at the meeting, ordered for commencement of the proceedings.

The Company Secretary welcomed the members present and introduced the Directors and KMPs, present at the meeting through Video Conferencing.

The Company Secretary informed the Members that the Company has extended the e-voting facility to the Members of the Company in respect of businesses to be transacted at the Annual General Meeting. The e-voting commenced at 09.00 a.m. on 21st August, 2021, and ended at 05.00 p.m. on 24th August, 2021.

Further the Members, who participated in the meeting and had not cast their votes through remote e-voting, were provided an opportunity to cast their votes through e-voting during the AGM.

The Company appointed CDSL, to provide e-voting facility and BVR & Associates Practising Company Secretaries LLP, Practicing Company Secretaries was appointed as the Scrutinizer for conducting the voting process through remote e-voting and e-voting during the AGM in a fair and transparent manner.

Pursuant to the provisions of the Companies Act, 2013 and the Secretarial Standards, the notice convening the Annual General Meeting was taken as read as the same had already been circulated to the Members.

Thereafter, the Chairman addressed the shareholders and delivered his speech on the business and performance highlights of the Company.

The Shareholders who had registered themselves as speakers were given the opportunity to ask questions and also seek clarification on the resolution to be passed during the AGM. They expressed their gratitude to the Chairman and the Company and the Chairman thanked all speakers.

Registered Office:

Balaxi Pharmaceuticals Limited

Thereafter, the following items specified in the Notice of the AGM were taken up for the

shareholders' consideration and adoption:

Resolution No.	Resolution description
Ordinary Business	
1.	To receive, consider and adopt the Audited Standalone and
	Consolidated Financial Statements for the Financial Year Ended 31st
	March, 2021, which includes the Balance Sheet, Statement of Profit &
	Loss, Cash Flow Statement as at that date, the Auditor's Report and the
	Board's Report thereon.
2.	To appoint a Director in place of Ms. Minoshi Maheshwari (DIN:
	01575975) who retires by rotation and being eligible, offers herself for
	re-appointment.
Special Business	
3.	Appointment of Mr. M. Srinivas Rao (DIN: 08095079) as an
	Independent Director
4.	Appointment of Ms. Purnima Singh Kamble (DIN: 00241708) as an
	Independent Director
5.	Re-appointment of Mr. Gandhi Gamji (DIN: 01944694) as an
	Independent Director for a second term of five consecutive years
6.	Re-appointment of Mr. Kunal Mahendra Bhakta (DIN: 01710557) as an
	Independent Director for a second term of five consecutive years

The Company Secretary informed the members that the consolidated results of the remote evoting and e-voting at the AGM would be announced within 48 hours of the conclusion of the meeting and also be intimated to the Stock Exchanges and posted on the website of the Company.

The Company Secretary informed that the E-voting facility was kept open for next 15 minutes to enable the Shareholders to cast their vote.

The Company Secretary thanked the shareholders for attending the AGM of the Company and declared the meeting as concluded.

Yours Faithfully,

For Balaxi Pharmaceuticals

Chinta Shalini Company Secretary

Registered Office:

Hyderab

2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096. CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

(Formerly known as Balaxi Ventures Limited)